



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** Anti-HIV-1 gp120 Monoclonal (268-D IV)

**Catalog Number:** 1511

**Lot Number:** 020743

**Release Category:** E

**Provided:** 0.5 ml tissue culture supernatant, 27.6 µg/mL.

**Host:** Human, EBV-transformed cells fused with heteromyeloma SHM-D33 cells

**Titer:** Use at 10-50 ng/ml for neutralization and

**Special Characteristics:** Both antibodies neutralize HIV-1<sub>MN</sub> infection of MT-2 cells.

**Recommended Storage:** Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

**Contributor:** Dr. Susan Zolla-Pazner.

**Isotype:** IgG<sub>1</sub>, λ.

**References:** Gorny MK, et al. *J Immunol* **150**:635-643, 1993.  
Gorny MK, et al *Proc Natl Acad Sci USA* **88**:3238-3242, 1991.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (268-D IV) from Dr. Susan Zolla-Pazner." Also include the references cited above in any publications.

Limited to 1 aliquot per laboratory. Patent pending. Corporate requests should be directed in writing to Dr. Susan Zolla-Pazner at the Veterans Administration Medical

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Research Chart**

Antibody	Cat. #	Lot	Conc.	Reactivity
257-D IV	1510	6 020742	10.7 µg/ml	Reacts with HIV-1 <sub>MN</sub> V3 epitope KRIHI. Cross-reacts with the V3 loop peptide (20-mer, American BioTechnologies) of HIV-1 SF-2, NY5, RF.
268-D IV	1511	6 020743	27.6 µg/ml	Reacts with the HIV-1 <sub>MN</sub> V3 epitope HIGPGR. Cross-reacts with the V3 loop peptide (20-mer, American BioTechnologies) of HIV-1 SF-2, NY5, RF, CDC4.

**Last Updated**

June 13, 2016

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.